Nyse american to commence delisting proceedings against navidea biopharmaceuticals, inc. (navb)

New york--(business wire)--nyse american llc (“nyse american” or the “exchange”) announced today that the staff of nyse regulation has determined to commence proceedings to delist the common stock of navidea biopharmaceuticals, inc. (the “company”) — ticker symbol navb —from the exchange. nyse regulation has determined that the company is no longer suitable for listing pursuant to section 1009(a) of the nyse american company guide (the “company guide”) as the company was unable to demonstrate t.
NAVB Ratings Summary
NAVB Quant Ranking